Clozapine in the Treatment of Neuroleptic-Induced Blepharospasm: A Report of 4 Cases
J Clin Psychiatry 2000;61(2):140-143
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Blepharospasm, the forcible closure
of eyelids, is an infrequent consequence of neuroleptic treatment
that, when severe, can interfere with the ability to walk, drive,
or work. Like tardive dyskinesia, blepharospasm can be
disfiguring and aesthetically distressing, contributing to the
increased stigmatization of patients.
Case Reports: We report 4 patients with DSM-IV
schizoaffective disorder, paranoid schizophrenia, or chronic
undifferentiated schizophrenia who developed neuroleptic-induced
blepharospasm. In all patients, blepharospasm remitted without
the reemergence of psychosis within 3 to 5 months of treatment
with clozapine, 100-200 mg/day.
Conclusion: The results suggest that clozapine
may successfully treat neuroleptic-induced blepharospasm without
the reemergence of psychosis in patients with schizophrenia,
schizoaffective disorder, or schizophreniform disorder.